CIAS

Volvo EX90 makes its Canadian debut at 2024 Canadian International Auto Show Electric City

Retrieved on: 
Thursday, February 15, 2024

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The 2024 Volvo EX90, Volvo Cars’ all-new, fully electric SUV, will be presented to the Canadian public for the first time at the Canadian International Auto Show (CIAS) in Toronto.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The 2024 Volvo EX90, Volvo Cars’ all-new, fully electric SUV, will be presented to the Canadian public for the first time at the Canadian International Auto Show (CIAS) in Toronto.
  • Volvo Car Canada will be exhibiting within the Electric City space, showcasing the ecosystem that supports a new age of mobility.
  • A new instant classic in Scandinavian design, the Volvo EX90 defines the principle of form following function:
    Safe space technology: The level of standard safety in the Volvo EX90 is higher than any Volvo car before it.
  • The 2024 Volvo EX90 will be available well-equipped starting at $110,000 with Volvo Car Canada’s One Price Promise.

Canadian International Air Show Celebrates 75 years of Soaring over Toronto

Retrieved on: 
Friday, February 9, 2024

TORONTO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Canadian International Air Show (CIAS) officially announces their 75th Anniversary performance headliners.

Key Points: 
  • TORONTO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Canadian International Air Show (CIAS) officially announces their 75th Anniversary performance headliners.
  • The 2024 initial lineup includes the Canadian Forces (CF) Snowbirds and the CF-18 Demonstration team along with the much-anticipated return of the Royal Air Force Aerobatic Team, Red Arrows, and the United States Air Force F-22 Raptor.
  • “For three-quarters of a century, the RCAF has been an integral part of our air show,” said Lori Duthie, Executive Director of the CIAS.
  • Tickets for the 75th Canadian International Air Show will go on sale in May 2024.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

Top 3 finalists in 4 categories announced for 2024 Canadian Car of the Year Awards

Retrieved on: 
Thursday, January 18, 2024

"Announcing these 12 finalists brings us one step closer to announcing the 2024 Canadian Car of the Year Awards.

Key Points: 
  • "Announcing these 12 finalists brings us one step closer to announcing the 2024 Canadian Car of the Year Awards.
  • We believe it shows Canadian drivers they can be confident in our results and in the Canadian Car of the Year program".
  • "We are excited to again be hosting the Canadian Car of the Year Awards with AJAC," said Jason Campbell, General Manager Canadian International AutoShow.
  • "We are thrilled to have Canadian Electric Car of the Year and Canadian Electric Utility Vehicle of the Year categories joining the established Canadian Car of the Year and Canadian Utility Vehicle of the Year awards.

Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Retrieved on: 
Thursday, January 4, 2024

NAARDEN, The Netherlands, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kynexis, a biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS). Kynexis expects to report preliminary data from the phase 1 study later this year.

Key Points: 
  • KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
  • Kynexis expects to report preliminary data from the phase 1 study later this year.
  • “Cognitive impairment is a major cause of disability for most people affected with schizophrenia, and there are currently no approved treatments for CIAS,” said Kees Been, Chief Executive Officer at Kynexis.
  • “KYN-5356 is potent, highly selective, and enters the CNS, solving the challenges of previous attempts at KAT-II inhibition.

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Tuesday, November 14, 2023

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

Key Points: 
  • NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
  • The on-going Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients with CIAS, with topline results expected in 2H 2024.
  • The poster will be presented at the American College of Neuropsychopharmacology (ACNP) annual meeting on Dec 5, 2023, 5:00 – 7:00 PM ET.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc.

AJAC announces semi-finalists for 2024 Canadian Car of the Year Awards

Retrieved on: 
Monday, December 4, 2023

CCOTY is Canada's ONLY vehicle awards scheme in which the jurors drive every vehicle they vote on.

Key Points: 
  • CCOTY is Canada's ONLY vehicle awards scheme in which the jurors drive every vehicle they vote on.
  • "The 20 AJAC Canadian Car of the Year Award semi-finalists are the vehicles that our members have found to be the cars, trucks, and SUVs best suited to the needs of drivers in Canada," said AJAC President Evan Williams.
  • After the finalists are announced in January, the winners to be revealed Thursday February 15, 2024 at the Canadian International AutoShow (CIAS) in Toronto.
  • "We are excited to again be partnering with AJAC for the Canadian Car of the Year Awards," said Jason Campbell, General Manager Canadian International AutoShow.

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
Tuesday, November 7, 2023

NAARDEN, The Netherlands, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, launched today with €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures. Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

Key Points: 
  • Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.
  • Dr. Schwarcz pioneered the study of the kynurenine pathway in the brain, which established kynurenine’s substantive role in cognition and in the pathophysiology of schizophrenia.
  • Through the convergence of human genetics, biomarkers, and deep phenotyping, Kynexis is well-positioned to pursue a novel, precision psychiatry-based approach to develop KYN-5356 in CIAS.
  • Under the terms of the agreement, Kynexis has an exclusive worldwide license from MTPC to develop and commercialize KYN-5356 worldwide.

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Retrieved on: 
Thursday, May 11, 2023

The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.

Key Points: 
  • The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026.
  • NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
  • “This past quarter we made significant progress, including the dosing of the first patient with RL-007 in a randomized, placebo-controlled Phase 2 study.
  • In January 2023, Phase 1 results were announced from the study of GRX-917 in healthy volunteers.

Soar into Labour Day at the 74th annual Canadian International Air Show

Retrieved on: 
Tuesday, May 9, 2023

TORONTO, May 09, 2023 (GLOBE NEWSWIRE) -- The Canadian International Airshow (CIAS) will once again return to Toronto’s waterfront from September 2-4 during the Labour Day weekend.

Key Points: 
  • TORONTO, May 09, 2023 (GLOBE NEWSWIRE) -- The Canadian International Airshow (CIAS) will once again return to Toronto’s waterfront from September 2-4 during the Labour Day weekend.
  • Despite announcing he would retire after last year’s event, the 81-year-old couldn’t stay grounded and has decided to return for one last show.
  • Tickets for the exclusive Air Show Zone are on sale now and guarantee the best possible spot to see all the action.
  • For additional information and to purchase tickets for the Canadian International Air Show, please visit cias.org .